Previous 10 | Next 10 |
3DMed test demonstrated 99.3% sensitivity and 100% specificity in Chinese clinical trial Nucleic Acid test performed on proprietary automated platform to increase throughput CE Mark and China FDA approval have been received; 3DMed in discussions with US FDA and...
3D BioMed test demonstrated 99.3% sensitivity and 100% specificity in Chinese clinical trial Nucleic Acid test performed on proprietary automated platform to increase throughput CE Mark and Chinese FDA approval have been received; 3D BioMed in discussions with US FDA T...
REHOVOT, Israel, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced it has entered into convertible no...
REHOVOT, Israel, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has received a notice of a...
REHOVOT, Israel, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today released a letter to shareholders: Dear S...
New York, NY, Feb. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary therapeutics and diagnostics, as well as CBD Wellness through its subs...
Strong customer retention at both stores in Dallas, TX with growing online presence Focus on delivering wellness solutions by engaging customers to participate in clinical studies and provide outcomes data to determine utility of branded CBD products ...
REHOVOT, Israel, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has entered into an exclus...
Emerald gains exclusive worldwide development rights to ESS, MANF and PhenoGuard Amarantus receives Emerald preferred stock valued at a minimum of $66.6 million New York, NY, Jan. 02, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings,...
NEW YORK, NY, Dec. 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company, developing first-in-class orphan neurologic, regenerative medicine a...
News, Short Squeeze, Breakout and More Instantly...
Amarantus BioScience Holdings Inc Company Name:
AMBS Stock Symbol:
OTCMKTS Market:
Amarantus BioScience Holdings Inc Website:
Board Member/Acting CEO Provides Shareholder Update Sale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation. Emphasis placed on advancing Elto Pharma, Inc. and MANF Therapeutics programs NEW YORK, NY / ACCESSWIRE / April 27, 2022 / Amarantus Bioscience Hol...
Significant progress in establishing COVID-19 PCR-based diagnostic testing business in US 3CL Protease-based saliva test making progress in Israel 3CL Protease inhibitor NLC-001 dietary supplement added to commercial portfolio 2019 convertible note holders and instituti...
NLC-001 is a proprietary blend of plant extracts administered orally as dietary supplement US FDA granted Certificate of Free Sale for NLC-001 on August 28, 2020 JV evaluating potential of NLC-001 to treat COVID-19 in clinical studies in Israel Todos e...